Drug Profile

Dupilumab biosimilar - Bio-Thera Solutions

Alternative Names: BAT-2406

Latest Information Update: 29 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bio-Thera Solutions
Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antifungals; Antineoplastics; Antipruritics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
Mechanism of Action Interleukin 4 receptor alpha subunit antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes - Autoimmune disorders

Highest Development Phases

Phase I Autoimmune disorders

Most Recent Events

25 Jul 2025 Phase-I clinical trials in Autoimmune disorders in China (Parenteral) (Bio-Thera Pharmaceuticals pipeline, July 2025)
25 Jun 2025 Dupilumab biosimilar licensed to SteinCares in Latin America
30 Aug 2024 NMPA approves clinical trial application for BAT 2406 in Autoimmune disorders (9446926)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com